Oladimeji Akinboro
3PUBLICATIONS
18CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (3)
Sort by Publication Date:
|Aug 11, 2025
US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Stage II and III High-Risk Early Breast Cancer Treatment Setting.Jennifer J Gao, Tatiana M Prowell, Haley Gittleman
|May 04, 2023
US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non-Small-Cell Lung Cancer.Oladimeji Akinboro, Nicole Drezner, Anup Amatya
|Feb 01, 2022
FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC.Oladimeji Akinboro, Erin Larkins, Lee H Pai-Scherf
Pageof 1
Frequent Collaborators
2 joint publications
Shenghui Tang
2 joint publications
Richard Pazdur
1 joint publications
Yuan Xu
1 joint publications
Rebecca Cohen
1 joint publications
Martha Donoghue
1 joint publications
Bronwyn Mixter
1 joint publications
Jennifer J Gao
1 joint publications
Tatiana M Prowell
1 joint publications
Haley Gittleman
1 joint publications
Ilynn Bulatao
